



Germany's Axiogenesis to collaborate with new San Antonio biotech company

[Cytocentrics](#) Inc. has entered into a business collaboration with Cologne, Germany-based Axiogenesis which could trigger additional economic development opportunities in San Antonio. Under the new deal, Cytocentrics will become the exclusive U.S. distributor of Axiogenesis' novel cardiomyocyte cell lines and American portal for the company's other stem cell products.

Through Axiogenesis' proprietary technology, the bioscience company can reprogram human skin or blood cells into embryonic-like stem cells.

Cytocentrics has combined bioscience, nano science, micro chip development, algorithms and engineering to develop and manufacture medical devices that support ion channel research and new approaches to disease analysis and personalized pharmacology. Last year, the company relocated its headquarters from Germany to San Antonio.

Cytocentrics CEO Dr. [James Garvin](#) said Axiogenesis' unique innovations, coupled with his company's ion channel capabilities, will help accelerate and improve the process of drug candidate selection and will prove to be a game-changer in personalized medicine.

"It continues to show the respect the market has for the technology and broadens our product set and footprint considerably," Garvin said when asked what impact the deal with Axiogenesis would have on Cytocentrics.

Axiogenesis CEO Dr. [Heribert Bohen](#) said the collaboration with Cytocentrics represents a breakthrough in stem cell development. He added that Cytocentrics was the "perfect strategic partner" in the U.S.

Garvin said the new agreement could lead to Axiogenesis moving some of its operations and jobs to San Antonio as the collaboration between the two companies expands.

Source: <http://www.bizjournals.com/sanantonio/news/2016/01/11/germany-s-axiogenesis-to-collaborate-with-new-san.html>

January 11th 2016